Hepatitis C Growth In Liver Cells Slowed By Protein

Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus. The anti-hepatitis C activity of the protein, called "p21-activated kinase 1" (PAK1), was discovered by scientists at the University of Texas Medical Branch at Galveston (UTMB), who describe their findings in an article in the current issue of the Journal of Biological Chemistry. In addition to presenting the researchers' discovery that PAK1 controls the rate at which hepatitis C virus replicates, the paper describes the biochemical pathways that lead to PAK1 activation and the specific mechanisms by which PAK1 interferes with the ability of hepatitis C to hijack liver cells and make more copies of itself. "Our findings reveal a novel cellular control pathway that regulates the growth of hepatitis C virus within the cell," said Dr. Stanley M. Lemon, director of the National Institutes of Health-funded Hepatitis C Research Center at UTMB and of the academic medical center's Institute for Human Infections and Immunity. Lemon, senior author of the Journal of Biological Chemistry paper, added, "Understanding this better is likely to suggest new approaches to therapy for this difficult to treat disease." ... Whole article "MedicalNewsToday":[ www.medicalnewstoday.com]

---

Related articles

Researcher Announced Cure for Hepatitis C - The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher said today (25.5.2007)

Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins - Hepatitis C virus (HCV) and triglyceride-rich very low-density lipoproteins (VLDLs) both are secreted uniquely by hepatocytes and circulate in blood in a complex (6.4.2007)

ViroPharma Announces Presentation Of New HCV-796 In Vitro Data At The 13th International Meeting On Hepatitis C Virus & Related Viruses - ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of additional preclinical data on HCV-796, an orally dosed non-nucleoside hepatitis C virus (HCV) polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), at the 13th International Meeting on Hepatitis C Virus & Related Viruses in Cairns, Australia (5.9.2006)

Genetic Test to Give Clues on Treatment of Hepatitis C - Celera Genomics plans to announce today that it has developed a genetic test it says can help predict which patients with hepatitis C will eventually suffer liver scarring and so are in most need of treatment (9.5.2006)